ArticleBMC infectious diseases2020

A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.

Collins C Iwuji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.